Emerging infections in transfusion medicine

Clinics in Laboratory Medicine

Volumn 24, Issue 3, 2004, Pages 797-823

  Fiebig, Eberhard W ^a,b   Busch, Michael P ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BABESIOSIS; BACTERIAL INFECTION; BACTERIUM CONTAMINATION; BLOOD; BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; BORRELIA BURGDORFERI; CHAGAS DISEASE; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; CYTOMEGALOVIRUS; DISEASE COURSE; DISEASE TRANSMISSION; HEALTH CARE POLICY; HEPATITIS VIRUS; HERPES SIMPLEX VIRUS; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION; INFECTION RISK; MALARIA; MEDICAL CARE; MEDICINE; MORTALITY; MOSQUITO; PARASITE; PARVOVIRUS; PATHOGENESIS; PRIORITY JOURNAL; RECIPIENT; RETROVIRUS; REVIEW; RISK ASSESSMENT; SAFETY; SCREENING TEST; TICK; TRANSFUSION; VIRUS ISOLATION; VIRUS STRAIN; WEST NILE FLAVIVIRUS;

BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; COMMUNICABLE DISEASES, EMERGING; HUMANS;

EID: 8444240726     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.05.009     Document Type: Review

References (111)

1. Schmidt P.J. Syphilis, a disease of direct transfusion. Transfusion. 41:(8):2001;1069-1071
2. Beeson P. Jaundice occurring one to four months after transfusion of blood or plasma. JAMA. 121:1943;1332-1334
3. Dodd R.Y., Notari E.P., Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 42:(8):2002;975-979
4. Glynn S.A., Kleinman S.H., Wright D.J., Busch M.P. International application of the incidence rate/window period model. Transfusion. 42:(8):2002;966-972
5. Alter H.J. Transfusion-transmitted hepatitis C and non-A, non-B, non-C virus infections. Simon T., Dzik W., Snyder E., Stowell C., Strauss R. Rossi's principles of transfusion medicine. 2002;718-732 Lippincott, Williams and Wilkins, Philadelphia
6. Dodd R.Y. Hepatitis A, hepatitis B, and non-A, non-B, non-C viruses. Hillyer C.D., Silberstein L.E., Ness P.M., Anderson K.C., Roush K.S. Blood banking and transfusion medicine. 2003;431-437 Churchill Livingstone, Philadelphia
7. Bower W.A., Nainan O.V., Han X., Margolis H.S. Duration of viremia in hepatitis A virus infection. J Infect Dis. 182:(1):2000;12-17
8. Xia N.S., Zhang J., Zheng Y.J., Ge S.X., Ye X.Z., Ou S.H. Transfusion of plasma from a blood donor induced hepatitis E in Rhesus monkey. Vox Sang. 86:(1):2004;45-47
9. Mateos M.L., Camarero C., Lasa E., Teruel J.L., Mir N., Baquero F. Hepatitis E virus: relevance in blood donors and risk groups. Vox Sang. 76:(2):1999;78-80
10. Diwan A.H., Stubbs J.R., Carnahan G.E. Transmission of hepatitis A via WBC-reduced RBCs and FFP from a single donation. Transfusion. 43:(4):2003;536-540
11. Hollinger F.B., Khan N.C., Oefinger P.E., Yawn D.H., Schmulen A.C., Dreesman G.R., et al. Posttransfusion hepatitis type A. JAMA. 250:(17):1983;2313-2317
12. Soucie J.M., Robertson B.H., Bell B.P., McCaustland K.A., Evatt B.L. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion. 38:(6):1998;573-579
13. Chudy M., Budek I., Keller-Stanislawski B., McCaustland K.A., Neidhold S., Robertson B.H., et al. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol. 57:(2):1999;91-99
14. Knezevic-Maramica I., Kruskall M.S. Intravenous immune globulins: an update for clinicians. Transfusion. 43:(10):2003;1460-1480
15. Thomas D.L., Nakatsuji Y., Shih J.W., Alter H.J., Nelson K.E., Astemborski J.A., et al. Persistence and clinical significance of hepatitis G virus infections in injecting drug users. J Infect Dis. 176:(3):1997;586-592
16. Feucht H.H., Zollner B., Polywka S., Knodler B., Schroter M., Nolte H., et al. Prevalence of hepatitis G viremia among healthy subjects, individuals with liver disease, and persons at risk for parenteral transmission. J Clin Microbiol. 35:(3):1997;767-768
17. Williams C.F., Klinzman D., Yamashita T.E., Xiang J., Polgreen P.M., Rinaldo C., et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med. 350:(10):2004;981-990
18. Umemura T., Yeo A.E., Sottini A., Moratto D., Tanaka Y., Wang R.Y., et al. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology. 33:(5):2001;1303-1311
19. Umemura T., Tanaka E., Ostapowicz G., Brown K.E., Heringlake S., Tassopoulos N.C., et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis. 188:(10):2003;1545-1552
20. Kleinman S., Busch M.P., Korelitz J.J., Schreiber G.B. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev. 11:(3):1997;155-172
21. Perrin L., Kaiser L., Yerly S. Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis. 3:(1):2003;22-27
22. Apetrei C., Loussert-Ajaka I., Descamps D., Damond F., Saragosti S., Brun-Vezinet F., et al. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS. 10:(14):1996;F57-F60
23. de Oliveira C.F., Diaz R.S., Machado D.M., Sullivan M.T., Finlayson T., Gwinn M., et al. Surveillance of HIV-1 genetic subtypes and diversity in the US blood supply. Transfusion. 40:(11):2000;1399-1406
24. Vrielink H., Zaaijer H.L., Reesink H.W. The clinical relevance of HTLV type I and II in transfusion medicine. Transfus Med Rev. 11:(3):1997;173-179
25. Blajchman M.A., Goldman M., Freedman J.J., Sher G.D. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev. 15:(1):2001;1-20
26. Hudnall S.D., Chen T., Rady P., Tyring S., Allison P. Human herpesvirus 8 seroprevalence and viral load in healthy adult blood donors. Transfusion. 43:(1):2003;85-90
27. Pellett P.E., Wright D.J., Engels E.A., Ablashi D.V., Dollard S.C., Forghani B., et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion. 43:(9):2003;1260-1268
28. Challine D., Roudot-Thoraval F., Sarah T., Laperche L., Boisson B., Mauberquez S., et al. Seroprevalence of human herpes virus 8 antibody in populations at high or low risk of transfusion, graft, or sexual transmission of viruses. Transfusion. 41:(9):2001;1120-1125
29. Kedes D.H., Operskalski E., Busch M., Kohn R., Flood J., Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 2:(8):1996;918-924
30. Belec L., Cancre N., Hallouin M.C., Morvan J., Si Mohamed A., Gresenguet G. High prevalence in Central Africa of blood donors who are potentially infectious for human herpesvirus 8. Transfusion. 38:(8):1998;771-775
31. Enbom M., Urassa W., Massambu C., Thorstensson R., Mhalu F., Linde A. Detection of human herpesvirus 8 DNA in serum from blood donors with HHV-8 antibodies indicates possible bloodborne virus transmission. J Med Virol. 68:(2):2002;264-267
32. Young N.S., Brown K.E. Parvovirus B19. N Engl J Med. 350:(6):2004;586-597
33. Azzi A., Morfini M., Mannucci P.M. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev. 13:(3):1999;194-204
34. Crane J. Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can. 24:(9):2002;727-743. [quiz: 744-6]
35. Brown K.E., Young N.S., Alving B.M., Barbosa L.H. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion. 41:(1):2001;130-135
36. Koenigbauer U.F., Eastlund T., Day J.W. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion. 40:(10):2000;1203-1206
37. Ragni M.V., Koch W.C., Jordan J.A. Parvovirus B19 infection in patients with hemophilia. Transfusion. 36:(3):1996;238-241
38. Blumel J., Schmidt I., Willkommen H., Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion. 42:(8):2002;1011-1018
39. Weimer T., Streichert S., Watson C., Groner A. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion. 41:(12):2001;1500-1504
40. Omar A., Kempf C. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion. 42:(8):2002;1005-1010
41. Berger A., Drosten C., Doerr H.W., Sturmer M., Preiser W. Severe acute respiratory syndrome (SARS) - paradigm of an emerging viral infection. J Clin Virol. 29:(1):2004;13-22
42. Centers for Disease Control and Prevention. Update: multistate outbreak of monkeypox - Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep. 52:(27):2003;642-646
43. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., Pham P.M., Nguyen V.C., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med. 350:(12):2004;1179-1188
44. Ng L.F., Wong M., Koh S., Ooi E.E., Tang K.F., Leong H.N., et al. Detection of severe acute respiratory syndrome coronavirus in blood of infected patients. J Clin Microbiol. 42:(1):2004;347-350
45. Klempner M.S., Shapiro D.S. Crossing the species barrier - one small step to man, one giant leap to mankind. N Engl J Med. 350:(12):2004;1171-1172
46. Welch J., Maclaran K., Jordan T., Simmonds P. Frequency, viral loads, and serotype identification of enterovirus infections in Scottish blood donors. Transfusion. 43:(8):2003;1060-1066
47. Petersen L.R., Marfin A.A. West Nile virus: a primer for the clinician. Ann Intern Med. 137:(3):2002;173-179
48. Biggerstaff B.J., Petersen L.R. Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City. Transfusion. 42:(8):2002;1019-1026
49. Centers for Disease Control and Prevention. West Nile virus 2002 case count. Available at: http://www.cdc.gov/ncidod/dvbid/westnile/ surv&controlCaseCount02.htm. Accessed April 6, 2004.
50. US Department of Health and Human Services. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). Revised recommendations for the assessment of donor suitability and blood and blood product safety in cases of known or suspected West Nile Virus infection. Available at: http://www.fda.gov/cber/gdlns/wnvguid.htm. Accessed April 6, 2004.
51. Iwamoto M., Jernigan D.B., Guasch A., Trepka M.J., Blackmore C.G., Hellinger W.C., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med. 348:(22):2003;2196-2203
52. Centers for Disease Control and Prevention. Update: West Nile virus screening of blood donations and transfusion-associated transmission - United States, 2003. MMWR Morb Mortal Wkly Rep. 53:(13):2004;281-284
53. Centers for Disease Control and Prevention. Division of Vector-Borne Infectious Diseases. Arboviral encephalitides. Available at: http://www.cdc.gov/ncidod/dvbid/arbor/index.htm. Accessed April 6, 2004.
54. Yomtovian R. Bacterial contamination of blood: lessons from the past and road map for the future. Transfusion. 44:(3):2004;450-460
55. Sugai Y., Sugai K., Fuse A. Current status of bacterial contamination of autologous blood for transfusion. Transfus Apheresis Sci. 24:(3):2001;255-259
56. Yomtovian R., Praprotnik D. Adverse consequences of autologous transfusion practice. Popovsky M. Transfusion reactions. 2001;261-314 AABB Press, Bethesda (MD)
57. Jacobs M.R., Palavecino E., Yomtovian R. Don't bug me: the problem of bacterial contamination of blood components - challenges and solutions. Transfusion. 41:(11):2001;1331-1334
58. Kuehnert M.J., Roth V.R., Haley N.R., Gregory K.R., Elder K.V., Schreiber G.B., et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 41:(12):2001;1493-1499
59. Brecher M.E., Heath D.G., Hay S.N., Rothenberg S.J., Stutzman L.C. Evaluation of a new generation of culture bottle using an automated bacterial culture system for detecting nine common contaminating organisms found in platelet components. Transfusion. 42:(6):2002;774-779
60. Yomtovian R., Lazarus H.M., Goodnough L.T., Hirschler N.V., Morrissey A.M., Jacobs M.R. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion. 33:(11):1993;902-909
61. Ness P.M. An incremental solution to bacterial contamination: taking the first step. Transfusion. 44:(3):2004;311-312
62. Bruneau C., Perez P., Chassaigne M., Allouch P., Audurier A., Gulian C., et al. Efficacy of a new collection procedure for preventing bacterial contamination of whole-blood donations. Transfusion. 41:(1):2001;74-81
63. McDonald C.P., Lowe P., Roy A., Robbins S., Hartley S., Harrison J.F., et al. Evaluation of donor arm disinfection techniques. Vox Sang. 80:(3):2001;135-141
64. Brecher M.E., Hay S.N. Improving platelet safety: bacterial contamination of platelets. Curr Hematol Rep. 3:(2):2004;121-127
65. Parola P., Raoult D. Ticks and tickborne bacterial diseases in humans: an emerging infectious threat. Clin Infect Dis. 32:(6):2001;897-928
66. McQuiston J.H., Paddock C.D., Holman R.C., Childs J.E. The human ehrlichioses in the United States. Emerg Infect Dis. 5:(5):1999;635-642
67. Cable R.G., Leiby D.A. Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases. Curr Opin Hematol. 10:(6):2003;405-411
68. Centers for Disease Control and Prevention. Division of Vector-Borne Infectious Diseases. CDC Lyme disease home page. Available at: http://www.cdc.gov/ncidod/dvbid/lyme/index.htm. Accessed April 28, 2004.
69. Gerber M.A., Shapiro E.D., Krause P.J., Cable R.G., Badon S.J., Ryan R.W. The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis. 170:(1):1994;231-234
70. Mettille F.C., Salata K.F., Belanger K.J., Casleton B.G., Kelly D.J. Reducing the risk of transfusion-transmitted rickettsial disease by WBC filtration, using Orientia tsutsugamushiin: a model system. Transfusion. 40:(3):2000;290-296
71. Shulman I., Haimowitz M. Transmission of parasitic infections by blood transfusion. Simon T., Dzik W., Snyder E., Stowell C., Strauss R. Rossi's principles of transfusion medicine. 2002;774-781 Lippincott, Williams and Wilkins, Philadelphia
72. Mollison P, Engelfriet C, Contreras M. Infectious agents transmitted by transfusion. In: Blood transfusion in clinical medicine. 9th edition. Oxford, UK: Blackwell Scientific Publications; 1993. p. 710-85.
73. Sibinga C.T. Transfusion medicine in developing countries. Transfus Med Rev. 14:(3):2000;269-274
74. Mungai M., Tegtmeier G., Chamberland M., Parise M. Transfusion- transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 344:(26):2001;1973-1978
75. Hadley T.J., Peiper S.C. From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood. 89:(9):1997;3077-3091
76. Silvie O., Thellier M., Rosenheim M., Datry A., Lavigne P., Danis M., et al. Potential value of Plasmodium falciparum-associated antigen and antibody detection for screening of blood donors to prevent transfusion-transmitted malaria. Transfusion. 42:(3):2002;357-362
77. Shehata N., Kohli M., Detsky A. The cost-effectiveness of screening blood donors for malaria by PCR. Transfusion. 44:(2):2004;217-228
78. Krause P.J. Babesiosis. Med Clin North Am. 86:(2):2002;361-373
79. Herwaldt B.L., McGovern P., Gerwel M., Easton R., MacGregor R. Endemic babesiosis in another Eastern state. New Jersey. Emerg Infect Dis. 9:(2):2003;184-188
80. Persing D.H., Herwaldt B.L., Glaser C., Lane R.S., Thomford J.W., Mathiesen D., et al. Infection with a babesia-like organism in northern California. N Engl J Med. 332:(5):1995;298-303
81. Lux J.Z., Weiss D., Linden J.V., Kessler D., Herwaldt B.L., Wong S.J., et al. Transfusion-associated babesiosis after heart transplant. Emerg Infect Dis. 9:(1):2003;116-119
82. Pantanowitz L., Telford S.R. III, Cannon M.E. The impact of babesiosis on transfusion medicine. Transfus Med Rev. 16:(2):2002;131-143
83. Moraes-Souza H., Bordin J.O. Strategies for prevention of transfusion-associated Chagas' disease. Transfus Med Rev. 10:(3):1996;161-170
84. Leiby D.A., Fucci M.H., Stumpf R.J. Trypanosoma cruzi in a low- to moderate-risk blood donor population: seroprevalence and possible congenital transmission. Transfusion. 39:(3):1999;310-315
85. Leiby D.A., Herron R.M. Jr., Read E.J., Lenes B.A., Stumpf R.J. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion. 42:(5):2002;549-555
86. Leiby D.A., Read E.J., Lenes B.A., Yund A.J., Stumpf R.J., Kirchhoff L.V., et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. J Infect Dis. 176:(4):1997;1047-1052
87. Umezawa E.S., Bastos S.F., Coura J.R., Levin M.J., Gonzalez A., Rangel-Aldao R., et al. An improved serodiagnostic test for Chagas' disease employing a mixture of Trypanosoma cruzi recombinant antigens. Transfusion. 43:(1):2003;91-97
88. Van Voorhis W.C., Barrett L.K., Eastman R.T., Alfonso R., Dupuis K. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (Amotosalen HCL) and long-wavelength UV. Antimicrob Agents Chemother. 47:(2):2003;475-479
89. Fabron A. Jr., Bordin J.O., Moraes-Souza H., Freymuller E., Lages-Silva E. Removal of Trypanosoma cruzi by white cell-reduction filters: an electronmicroscopic study. Rev Soc Bras Med Trop. 32:(3):1999;223-227
90. Corash L. Pathogen reduction technology: methods, status of clinical trials, and future prospects. Curr Hematol Rep. 2:(6):2003;495-502
91. Dodd R.Y. Pathogen inactivation: mechanisms of action and in vitro efficacy of various agents. Vox Sang. 83:(Suppl 1):2002;267-270
92. Prusiner S.B. Shattuck lecture - neurodegenerative diseases and prions. N Engl J Med. 344:(20):2001;1516-1526
93. Ricketts M.N., Cashman N.R., Stratton E.E., ElSaadany S. Is Creutzfeldt-Jakob disease transmitted in blood? Emerg Infect Dis. 3:(2):1997;155-163
94. Turner M.L., Ludlam C.A. Variant Creutzfeldt-Jakob disease. Transfus Med Rev. 14:(3):2000;216-222
95. Dodd R.Y., Busch M.P. Animal models of bovine spongiform encephalopathy and vCJD infectivity in blood: two swallows do not a summer make. Transfusion. 42:(5):2002;509-512
96. US Department of Health and Human Services. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). Revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob Disease (CJD) and variant Creutzfeldt-Jakob Disease (vCJD) by blood and blood products. Available at: http://www.fda.gov/cber/gdlns/cjdvcjd.htm. Accessed April 9, 2004.
97. The UK Creutzfeldt-Jakob Disease Surveillance Unit. Creutzfeldt-Jakob disease surveillance. Available at: http://www.cjd.ed.ac.uk. Accessed April 9, 2004.
98. Centers for Disease Control and Prevention. Probable variant Creutzfeldt-Jakob disease in a US resident - Florida, 2002. MMWR Morb Mortal Wkly Rep. 51:(41):2002;927-929
99. Llewelyn C.A., Hewitt P.E., Knight R.S., Amar K., Cousens S., Mackenzie J., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 363:(9407):2004;417-421
100. Brown P. Variant CJD transmission through blood: risks to predictors and "predictees." Transfusion. 43:(4):2003;425-427
101. Jackson B.R., Busch M.P., Stramer S.L., AuBuchon J.P. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion. 43:(6):2003;721-729
102. AuBuchon J.P. Pathogen inactivation in cellular blood components: clinical trials and implications of introduction to transfusion medicine. Vox Sang. 83:(Suppl 1):2002;271-275
103. Kleinman S. Transfusion safety when you don't know what you are looking for: issues related to emerging pathogens. Stramer S. Blood safety in the new millennium. 2001;79-96 American Association of Blood Banks, Bethesda (MD)
104. Busch M., Chamberland M., Epstein J., Kleinman S., Khabbaz R., Nemo G. Oversight and monitoring of blood safety in the United States. Vox Sang. 77:(2):1999;67-76
105. Williamson L.M. Using haemovigilance data to set blood safety priorities. Vox Sang. 83:(Suppl 1):2002;65-69
106. Andreu G., Morel P., Forestier F., Debeir J., Rebibo D., Janvier G., et al. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 42:(10):2002;1356-1364
107. Chamberland M.E., Alter H.J., Busch M.P., Nemo G., Ricketts M. Emerging infectious disease issues in blood safety. Emerg Infect Dis. 7:(Suppl 3):2001;552-553
108. Mine H., Emura H., Miyamoto M., Tomono T., Minegishi K., Murokawa H., et al. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods. 112:(1-2):2003;145-151
109. Seifarth W., Spiess B., Zeilfelder U., Speth C., Hehlmann R., Leib-Mosch C. Assessment of retroviral activity using a universal retrovirus chip. J Virol Methods. 112:(1-2):2003;79-91
110. Wang D., Urisman A., Liu Y.T., Springer M., Ksiazek T.G., Erdman D.D., et al. Viral discovery and sequence recovery using DNA microarrays. PLoS Biol. 1:(2):2003;E2
111. Anderson N.G., Gerin J.L., Anderson N.L. Global screening for human viral pathogens. Emerg Infect Dis. 9:(7):2003;768-774